Physician profile
Leon Gallow
NPI 1568554897
$930.69
in general payments reported to CMS, 2019-2025
15 companies · $99.25 in 2025
The $99.25 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.76 · 2022: $233 · 2023: $331 · 2024: $247 · 2025: $99.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $218.90 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $150.32 | 2023-2024 | Tezspire, Farxiga, Breztri |
| Abbott Laboratories | $75.72 | 2021-2023 | Freestyle Libre 3 |
| Coloplast Corp | $74.43 | 2023 | Titan |
| Amgen INC. | $72.98 | 2023-2025 | Evenity, Prolia, Otezla |
| Boston Scientific Corporation | $69.30 | 2023 | Resonate El Icd Vr |
| Cardiovascular Systems INC. | $55.42 | 2022 | |
| Abbvie INC. | $47.86 | 2023 | |
| Lilly USA, LLC | $45.96 | 2022-2023 | Mounjaro |
| Ardelyx, INC. | $39.66 | 2024-2025 | Ibsrela |
| Dexcom, INC. | $19.58 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $17.05 | 2025 | Flucelvax, Fluad |
| Aytu Biopharma, INC. | $15.34 | 2024 | Karbinal |
| Glaxosmithkline, LLC. | $14.29 | 2024 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.88 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Gallow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.